News | September 24, 2025
Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Importantly, the combination of giredestrant and everolimus was well tolerated
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Subscribe To Our Newsletter & Stay Updated
